Eris Lifesciences Limited

Eris Lifesciences Schedules Analyst & Investor Call for Q3 FY2026 Results on Feb 13

Eris Lifesciences will host an analyst and investor call on February 13, 2026, at 5:30 PM IST. The call will discuss the standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2025.

Eris Lifesciences Allots 23.06 Lakh Shares for Swiss Parenterals Acquisition

Eris Lifesciences allotted 23,06,372 equity shares at ₹1835.35 each to Mr. Naishadh Shah. This is for acquiring 16,74,493 shares of Swiss Parenterals, making it a wholly-owned subsidiary. The company's paid-up capital increased to ₹13.85 crore.

Eris Lifesciences files SEBI compliance certificate for Q3 FY26

Eris Lifesciences Limited submitted a SEBI compliance certificate for the quarter ended December 31, 2025. The certificate, received from RTA MUFG Intime India Private Limited, confirms the processing and listing of dematerialised securities.

Eris Lifesciences: Trading Window Closed Jan 1, 2026, for Q3 FY26 Results

Eris Lifesciences Limited will close its trading window from January 1, 2026. The window will reopen 48 hours after the declaration of unaudited financial results for the quarter and nine months ending December 31, 2025. Designated persons are restricted from trading securities during this period.

Eris Lifesciences shareholders approve director re-appointments and preferential issue

Eris Lifesciences shareholders approved the re-appointment of Mr. Krishnakumar Vaidyanathan as Whole-Time Director and Ms. Kalpana Unadkat as Independent Director. Shareholders also approved the preferential issuance of up to 23,06,372 equity shares and material related party transactions with Mr. Naishadh Shah. All resolutions passed with a significant majority.

Eris Lifesciences: Independent Director Rajeev Dalal's Term Ends Dec 18

Eris Lifesciences Limited announces that Mr. Rajeev Dalal's term as Non-Executive, Independent Director ends on December 18, 2025. He was appointed for a five-year term starting December 19, 2020. His directorship and committee memberships will cease on this date.

Eris Lifesciences: Second Corrigendum to Postal Ballot Notice Issued

Eris Lifesciences Limited issued a second corrigendum to its Postal Ballot Notice dated November 24, 2025. An updated valuation report dated December 17, 2025, has been issued, removing references to DCF methodology. E-voting ends December 24, 2025. No change in share valuation or swap ratio.

Eris Lifesciences to Attend Investor Meet on Dec 18, 2025

Eris Lifesciences will attend a virtual investor group meeting on December 18, 2025, organized by BOB Capital Markets. Ms. Kruti Raval will represent the company. Publicly available documents will be used, and no UPSI will be discussed. Several institutional investors are expected to participate.

Clarification on Increase in Volume

Eris Lifesciences clarifies that the increase in share volume is due to market conditions, with all material info already disclosed as per SEBI regulations.

Corrigendum to Postal Ballot Notice Issued on November 24, 2025

Eris Lifesciences issued a corrigendum to its postal ballot notice, providing clarifications, additional disclosures, and a revised valuation report. Members can modify their votes until December 24, 2025.

Eris Lifesciences Announces Corporate Presentation

Eris Lifesciences announced its corporate presentation covering business overview, domestic formulations, manufacturing, and international operations. It highlights expansion plans for insulin capacity and targets a debt-to-EBITDA ratio of <1.5x by Dec 2026.

Eris Lifesciences Limited: Newspaper Publication of Postal Ballot Notice

Eris Lifesciences publishes notice of electronic dispatch of Postal Ballot in Financial Express on November 25, 2025, as per SEBI regulations. Notice is on company website, BSE, NSE, and NSDL.

Eris Lifesciences Announces Postal Ballot for Key Resolutions

Eris Lifesciences announces postal ballot for member approval on resolutions including director re-appointments and share issuance, with e-voting concluding on December 24, 2025.

Eris Lifesciences to Acquire Remaining Stake in Swiss Parenterals via Share Swap

Eris Lifesciences to acquire remaining 30% stake in Swiss Parenterals for ₹423.30 crore via share swap, issuing 23.06 lakh shares to Mr. Naishadh Shah. Postal ballot scheduled; completion expected by March 31, 2026.

Eris Lifesciences to Acquire Remaining 30% Stake in Swiss Parenterals

Eris Lifesciences to acquire remaining 30% stake in Swiss Parenterals for ₹423.30 crore via share swap, pending shareholder approval.

Eris Lifesciences to Acquire Remaining Stake in Swiss Parenterals

Eris Lifesciences to acquire the remaining 30% stake in Swiss Parenterals for ₹423.30 crore via share swap, pending shareholder approval.

Eris Lifesciences to participate in Avendus Spark INDX and Kotak Midcap investor conferences

Eris Lifesciences management will participate in Avendus Spark INDX and Kotak Midcap investor conferences on November 19 and 20, 2025, in Mumbai, for 1x1 and group meetings.

Eris Lifesciences releases transcript of Q2FY26 analyst and investor call

Eris Lifesciences released the transcript of its Q2FY26 analyst and investor call, held after the announcement of financial results for the quarter and half year ended September 30, 2025.

Eris Lifesciences Announces Availability of Q2 FY26 Earnings Concall Recording

Eris Lifesciences announced the availability of the Q2 FY26 earnings conference call recording, held on November 12, 2025, for the quarter ended September 30, 2025, on its website.

Eris Lifesciences Board Approves Results, Re-appoints Directors

Eris Lifesciences board approves unaudited financial results for the quarter ended September 20, 2025. Reappoints Krishnakumar Vaidyanathan as Whole Time Director and Kalpana Unadkat as Independent Director.

Eris Lifesciences Reports Strong Q2 & H1 FY26 Consolidated Results; Directors Re-appointed

Eris Lifesciences reported strong Q2 and H1 FY26 consolidated financial results with significant growth in revenue and profit. The Board also recommended re-appointments of two directors.

Eris Lifesciences Investor Presentation - Q2 FY26

Eris Lifesciences releases its investor presentation for Q2 FY26, reporting revenue and EBIDTA growth. Key highlights include expansion of insulin capacity and strategic partnerships.

Eris Lifesciences Approves Re-appointments & Unaudited Results for Sep 20, 2025

Eris Lifesciences board approves unaudited results for quarter ended September 20, 2025, and re-appoints Krishnakumar Vaidyanathan as Whole Time Director and Kalpana Unadkat as Independent Director.

Eris Lifesciences Announces Analyst and Investor Conference Call on 12 Nov 2025

Eris Lifesciences Limited will hold a conference call for analysts and investors on November 12, 2025, at 04:30 P.M. IST to discuss financial results for the quarter and half year ended September 30, 2025.

Certificate under SEBI Regulations for Quarter Ended 30th September 2025

Eris Lifesciences Limited submits a certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2025, confirming the dematerialization of securities.

Eris Lifesciences Secures ANVISA Approval for Ahmedabad Unit, Enabling Entry into Brazil's Pharma Market

Eris Lifesciences Receives Show Cause Notice for Alleged IGST Non-Payment

Eris Lifesciences to hold investor meetings in Singapore and Hong Kong

Eris Lifesciences Announces Transcript of Analyst and Investor Call

Eris Lifesciences Q1 FY26 Earnings Conference Call Recording Available Online

Eris Lifesciences Approves Unaudited Standalone & Consolidated Results

Eris Lifesciences to hold investor call on 5 Aug 2025 at 5:30 PM IST

Eris Lifesciences: Proceedings of 19th Annual General Meeting